Abstracts tagged "Bone density"

Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting
Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture
Anna Lafian¹, Julia Suh² and Karina Torralba³, ¹Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, ²Internal Medicine, Loma Linda University, Loma Linda, CA, ³Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
Abstract Number: 1886 • 2017 ACR/ARHP Annual Meeting
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
E Michael Lewiecki¹, Rajani V Dinavahi², Marise Lazaretti-Castro³, Peter R Ebeling⁴, J Adachi⁵, Akimitsu Miyauchi⁶, Evelien Gielen⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of São Paulo, São Paulo, Brazil, ⁴Monash University, Melbourne, Australia, ⁵McMaster University, Hamilton, ON, Canada, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷University Hospitals Leuven, Leuven, Belgium, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…
Abstract Number: 1937 • 2017 ACR/ARHP Annual Meeting
Abaloparatide, an Osteoanabolic PTHrP Analog, Increased Bone Mineral Density in Rabbits with Glucocorticoid Induced Osteopenia
Heidi Chandler¹, Allen Pierce², Jeffery Brown², Michael Ominsky² and Gary Hattersley³, ¹Research, Radius Health Inc, Waltham, MA, ²Radius Health Inc, Waltham, MA, ³Radius Health, Inc., Waltham, MA
Background/Purpose: Estrogen deficiency and glucocorticoid (GC) therapy are the main causes of postmenopausal and secondary osteoporosis, respectively. Bone loss in both states relate to a…
Abstract Number: 2002 • 2017 ACR/ARHP Annual Meeting
Baseline 18F Sodium Fluoride Uptake of Vertebral Bodies but Not Vertebral Corners on Positron Emission Tomography Is Associated with Changes in Bone Mineral Density at Lumbar Vertebrae in Ankylosing Spondylitis: A 1-Year Longitudinal Study
Seung-Geun Lee¹, Keunyoung Kim², Seong-Min Kweon³, Eun-Kyoung Park⁴, Yun-Kyung Kim⁵ and Geun-Tae Kim⁶, ¹Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), ²Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea, Republic of (South), ³Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea, Busan, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea, Republic of (South), ⁵Internal Medicine, Kosin University College of Medicine, Busan, South Korea, Busan, Korea, Republic of (South), ⁶Kosin University College of Medicine, Busan, Korea, Republic of (South)
Background/Purpose: 18F sodium fluoride (NaF) positron emission tomography (PET) allows quantitative assessment of osteoblastic bone synthesis in specific skeletal sites. Previous studies showed that increased…
Abstract Number: 2201 • 2017 ACR/ARHP Annual Meeting
Baseline Periarticular Tibial Knee Bone Mineral Density Is Associated with Change in Static Alignment
Grace H. Lo¹, Jeffrey B. Driban², Michael T. Strayhorn³, Lori Lyn Price⁴, Charles Eaton⁵ and Timothy E. McAlindon⁶, ¹Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, ²Rheumatology, Tufts Medical Center, Boston, MA, ³VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ⁴Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, ⁵Family Medicine and Epidemiology, Warren Alpert Medical School, School of Public Health, Brown University, Providence, RI, ⁶Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Relative local knee periarticular bone mineral density (paBMD) as measured by dual x-ray absorptiometry (DXA) has been associated with static alignment cross-sectionally, but not…
Abstract Number: 2367 • 2017 ACR/ARHP Annual Meeting
The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis: a Systematic Review and Meta-Analysis
Anne-Birgitte Blavnsfeldt^1,2, Malissa Dawn Thomsen³, Simon Tarp⁴, Bente Langdahl^2,5, Ellen-Margrethe Hauge^2,6 and Annette de Thurah^7,8, ¹Rheumatology, Aarhus Universityhospital, Aarhus C, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark, ³Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ⁴The Parker Institute, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark, ⁵Endocrinology, Aarhus University Hospital, Aarhus, Denmark, ⁶Aarhus Universityhospital, Aarhus C, Denmark, ⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: The role of glucocorticoids (GCs) in the treatment of rheumatoid arthritis (RA) is widely debated. GCs stimulate bone resorption and impair bone formation. Inflammatory…
Abstract Number: 2L • 2016 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
K Saag¹, RB Wagman², P Geusens³, JD Adachi⁴, O Messina⁵, R Emkey⁶, R Chapurlat⁷, NS Daizadeh², N Pannacciulli² and WF Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aires, Argentina, ⁶Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment.…
Abstract Number: 2986 • 2016 ACR/ARHP Annual Meeting
Trends and Determinants of Osteoporosis Prevention and Management in Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Gulsen Ozen^1,2, Diane L. Kamen³, Ted R Mikuls², Frederick Wolfe⁴ and Kaleb Michaud^2,4, ¹Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Despite more aggressive treatment strategies and new biologic DMARDs, the prevalence of osteoporosis (OP) leading to fracture in RA remains high. It is unknown…
Abstract Number: 2 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Related Autoimmunity and Lumbar Bone Mineral Density in a Multi-Ethnic Community-Dwelling Population
Jan M. Hughes-Austin¹, Joachim H. Ix², Michael H. Criqui³, Ronit Katz⁴, Matthew Budoff⁵, Jon T. Giles⁶, Kiang Liu⁷ and Darcy S. Majka⁸, ¹Orthopaedic Surgery, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴University of Washington, Seattle, WA, ⁵Cardiology, Harbor-UCLA Medical Center, Torrance, CA, ⁶Rheumatology, Columbia University Medical Center, NY, NY, ⁷Department of Preventive Medicine, Northwestern University, Chicago, IL, ⁸Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Previous studies suggest that antibodies to citrullinated protein antigens (ACPA) contribute to decreased hand bone mineral density (BMD) in RA-free individuals. No evidence exists…
Abstract Number: 4 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA)-Related Joint Symptoms and Thoracic Bone Mineral Density in an RA-Free Community Dwelling Population
Jan M. Hughes-Austin¹, Joachim H. Ix², Samuel R. Ward³, M. Kristen Demoruelle⁴, V. Michael Holers⁵, Jill M. Norris⁶ and Kevin D. Deane⁷, ¹Orthopaedic Surgery, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Radiology, Orthopaedic Surgery, and Bioengineering, University of California, San Diego, La Jolla, CA, ⁴1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁵Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁶University of Colorado Denver, Aurora, CO, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Osteoporosis, defined by Tscore < -2.5, is one of the main consequences of RA and it appears early in the disease. It is twice…
Abstract Number: 167 • 2016 ACR/ARHP Annual Meeting
Bone Mineral Density Loss in Clinically Suspect Arthralgia Is Associated with Subclinical Inflammation and Progression to Clinical Arthritis
L. Mangnus¹, H.W. van Steenbergen², M. Reijnierse³, J. Kälvesten^4,5,6 and A.H.M. van der Helm-van Mil², ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Radiology, Faculty of Health Sciences, Linköping, Sweden, ⁵Center for Medical Image Science and Visualization, Linköping University, Linköping, Sweden, ⁶Sectra AB, Linköping, Sweden
Background/Purpose: Peripheral bone mineral density (BMD) can be decreased in early rheumatoid arthritis but it is unknown if BMD loss emerges already before arthritis is…
Abstract Number: 321 • 2016 ACR/ARHP Annual Meeting
Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis
EM Lewiecki¹, S Horlait², T Blicharski³, S Goemaere⁴, K Lippuner⁵, P Meisner⁶, PD Miller⁷, A Miyauchi⁸, J Maddox⁹, NS Daizadeh⁹ and A Grauer⁹, ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Ltd., Uxbridge, United Kingdom, ³Medical University of Lublin, Lublin, Poland, ⁴Ghent University Hospital, Gent, Belgium, ⁵Bern University Hospital, Bern, Switzerland, ⁶UCB Pharma, Brussels, Belgium, ⁷Colorado Center for Bone Research, Lakewood, CO, ⁸Miyauchi Medical Center, Osaka, Japan, ⁹Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing…
Abstract Number: 343 • 2016 ACR/ARHP Annual Meeting
Correlation Between Metacarpal Cortical Bone Mineral Density Measured By Dual X-Ray Densitometry and Radiogrammetry on Early Arthritis Patients
Irene Llorente Cubas*¹, Leticia Merino-Meléndez², Ana M. Ortiz Garcia³, Saturnino González Ortega⁴, Eugenio Escolano⁵, Alberto Garcia-Vadillo⁶, Esther Vicente-Rabaneda², Rosario Garcia-Vicuña⁶, Isidoro Gonzalez-Alvaro³ and Santos Castañeda⁷, ¹Rheumatology, H.U La Princesa, Madrid, Spain, ²Rheumatology, H.U. La Princesa, Madrid, Spain, ³Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁴X-ray diagnosis, X-ray diagnosis, Hospital de La Princesa, Madrid, Spain, ⁵Radiology Department, H.U La Princesa, Madrid, Spain, ⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁷Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain
Background/Purpose: Low bone mass at metacarpal (MC) diaphysis measured by radiogrammetry (DXR) has been described as a poor prognostic factor in rheumatoid arthritis (RA). However,…
Abstract Number: 350 • 2016 ACR/ARHP Annual Meeting
Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis
Linda Rasch¹, Lilian van Tuyl¹, Martijn Kremer², Irene E.M. Bultink², Maarten Boers^3,4 and Willem F. Lems^1,4, ¹Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Recently, we showed that treatment with COBRA-light therapy including prednisone with initially 30 mg/day, was as effective as the original COBRA scheme, with initially…
Abstract Number: 359 • 2016 ACR/ARHP Annual Meeting
The Association of Scheuermann’s Disease with Osteoporotic Vertebral Fracture Risk
Marine Gaudé¹, R Chapurlat² and Pawel Szulc³, ¹Rheumatology, INSERM UMR 1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, ²INSERM UMR 1033 and University of Lyon, Hôpital Edouard Herriot, Lyon, France, ³Epidemiology of Osteoporosis, INSERM UMR 1033, Lyon, France
Background/Purpose: Scheuermann’s disease is one of the most frequent illnesses of the spine in teenagers. Its evolution over time is poorly understood. Spinal deformities, by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].